Back
Sarepta Therapeutics Inc (SRPT)
BiotechnologySRPT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$17.85
−2.03%Weekly undervalued picks (like SRPT)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-7.13
ROE
4.9%
Gross margin
21.6%
Debt/Equity
0.70x
Revenue growth
-1.9%
Sarepta Therapeutics Inc — company intelligence
Earnings surprises
Q2 2026$-0.05 vs $0.26 est-119.0%
Q1 2026$2.88 vs $1.01 est+184.7%
Q4 2025$-3.93 vs $-1.26 est-213.0%
Q3 2025$-0.01 vs $-0.83 est+98.8%
Analyst consensus · 33 analysts
14 Buy13 Hold6 Sell
Updated Sep 25, 2026
Insider activity · 90 days
2 buys0 sellsnet +2,980,446 shares
SEVERINO MICHAELBuy 756,104 · Jul 28, 2026
SEVERINO MICHAELBuy 2,224,342 · Jul 28, 2026
Recent SEC filings
8-K — Material event reportSep 23, 2026
4 — Insider transaction reportSep 8, 2026
4 — Insider transaction reportSep 8, 2026
Latest news
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17 — Benzinga · 2d ago
Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics — Yahoo · 3d ago
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’ — Benzinga · 4d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like SRPT)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.